1. Li Z, Shah DK (2019) Two-pore physiologically based pharmacokinetic model with de novo derived parameters for predicting plasma PK of different size protein therapeutics. J Pharmacokinet Pharmacodynam 46(3):305–318
2. U.S. Food and Drug Administration (2018) Physiologically based pharmacokinetic analyses—format and content guidance for industry. Center for Drug Evaluation and Research, Silver Spring
3. Glassman PM, Balthasar JP (2019) Physiologically-based modeling of monoclonal antibody pharmacokinetics in drug discovery and development. Drug Metab Pharmacokinet 34(1):3–13
4. Covell DG, Barbet J, Holton OD, Black CD, Parker R, Weinstein JN (1986) Pharmacokinetics of monoclonal immunoglobulin G1, F (ab′) 2, and Fab′ in mice. Cancer Res 46(8):3969–3978
5. Baxter LT, Zhu H, Mackensen DG, Jain RK (1994) Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice. Cancer Res 54(6):1517–1528